Overview

Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder

Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates the use of Rhodiola rosea in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in adults. Half of participants will receive Rhodiola rosea, while the other half will receive placebo.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Criteria
Inclusion Criteria:

- Fulfillment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,
(DSM-5) diagnostic criteria for ADHD in Adults

- Intelligence Quotient (IQ) above 70

- Eligibility to Rhodiola rosea

Exclusion Criteria:

- clinical contraindication fro Rhodiola rosea -

- any unstable chronic illness without proper treatment (hypertension, heart, kidney or
liver disease)

- any significant neurological disease (delirium, dementia, epilepsy, AIDS, head trauma,
multiple sclerosis, stroke, etc)

- unstable psychiatric comorbidities requiring immediate treatment (risk of suicide,
current Substance Use Disorder, etc.)

- pregnant, nursing or absence of reliable contraception

- current use of nicotine (<30 days)

- use of anticoagulants

- current use of any psychoactive drug (<30 days)

- prior use of stimulants

- current or lifetime psychosis- current or lifetime bipolar disorder